Jürgen Frevert, Ph.D.
Jürgen Frevert, Ph.D., is a chemist and biochemist whose work connects the NT201 development program with Xeomin and Merz’s botulinum toxin research history.
Frevert is relevant as a product-development and formulation-science figure, not as Merz’s current corporate leader. Philip Burchard represents Merz Group leadership and Bob Rhatigan represents Merz Aesthetics leadership; Frevert explains part of the scientific pathway behind incobotulinumtoxinA.
Role Context
Section titled “Role Context”| Field | Detail |
|---|---|
| Professional field | Chemistry, biochemistry, and botulinum toxin research |
| Historical organizations | BioteCon Therapeutics GmbH and Merz Pharmaceuticals GmbH |
| Development program | NT101 / NT201 |
| Product connection | Xeomin and Bocouture market context |
| Relevant company | Merz Pharma |
| Industry relevance | Product development, characterization, and formulation-science history |
NT201 and Xeomin Development
Section titled “NT201 and Xeomin Development”A public IMCAS scientific profile 🔗 describes Frevert as a project manager and later Chief Scientific Officer at BioteCon Therapeutics between 1995 and 2006, with responsibility for NT101 / NT201 development. It also identifies his later role as Head of Botulinum Toxin Research at Merz Pharmaceuticals.
NT201 became associated with the incobotulinumtoxinA product marketed as Xeomin, while Bocouture is an aesthetic-market name used in some countries. Those names belong to related development and market contexts, but each product claim still depends on the relevant local authorization and product information.
Merz’s corporate history 🔗 records the 2005 introduction of its type A botulinum toxin product. That company milestone provides the commercial context around the development program; it does not make one researcher solely responsible for the final regulated product.
Product Science and Formulation Context
Section titled “Product Science and Formulation Context”Frevert’s 2009 paper, “Xeomin: an innovative new botulinum toxin type A” 🔗, identified him as Head of Botulinum Toxin Research at Merz Pharmaceuticals and discussed NT201 / Xeomin product characteristics.
This literature is useful for tracing how Merz described and studied the product. It should not be treated as independent proof that Xeomin is safer, stronger, longer-lasting, less immunogenic, or clinically superior to Botox, Dysport, or another toxin product. Formulation features and clinical outcomes require separate, product-specific evidence.
Separating Development from Current Company Roles
Section titled “Separating Development from Current Company Roles”Frevert’s page fills a gap that executive biographies cannot. A parent-company CEO explains governance, and a business-unit CEO explains commercialization, but neither role by itself explains the research and development history of NT201.
The same distinction applies in reverse: participation in product development does not establish current ownership, manufacturing responsibility, label authority, or commercial leadership. Current Xeomin company and manufacturing claims should remain anchored to Merz sources and prescribing information.
Activity and Public Context
Section titled “Activity and Public Context”Frevert has published on botulinum toxin characterization, formulation, potency, and product comparison. Those publications are useful for product-science history when their company affiliation and study context remain visible.
For current product identity, approved uses, warnings, dosing language, and unit cautions, continue to Xeomin and the applicable prescribing information. Xeomin units remain product-specific and cannot be converted directly into units of another botulinum toxin product.